Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

被引：0
|
作者：
Ding, Qian [1 ]
Guan, Ming-Cheng [1 ]
Zhu, Hong [1 ,2 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[2] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, 899,Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2023年 / 192卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.ejca.2023.113263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
    Toshida, Katsuya
    Itoh, Shinji
    Tomiyama, Takahiro
    Morinaga, Akinari
    Kosai, Yukiko
    Tomino, Takahiro
    Kurihara, Takeshi
    Nagao, Yoshihiro
    Morita, Kazutoyo
    Harada, Noboru
    Yoshizumi, Tomoharu
    JGH OPEN, 2022, 6 (07): : 477 - 486
  • [42] Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
    Cheon, J.
    Ryoo, B-Y.
    Kim, H-D.
    Kim, K-P.
    Ryu, M. H.
    Chon, H. J.
    Kang, B.
    Finn, R. S.
    Yoo, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1536
  • [43] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [44] Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study
    Storandt, Michael H.
    Zemla, Tyler J.
    Patell, Kanchi
    Naleid, Nikolas
    Gile, Jennifer J.
    Tran, Nguyen H.
    Chakrabarti, Sakti
    Jin, Zhaohui
    Borad, Mitesh
    Mahipal, Amit
    ONCOLOGIST, 2024, 29 (11): : 986 - 996
  • [45] Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
    Rimini, Margherita
    Stefanini, Bernardo
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Finkelmeier, Fabian
    Yoo, Changhoon
    Presa, Jose
    Amadeo, Elisabeth
    Genovesi, Virginia
    De Grandis, Maria Caterina
    Iavarone, Massimo
    Marra, Fabio
    Foschi, Francesco
    Tamburini, Emiliano
    Rossari, Federico
    Vitiello, Francesco
    Bartalini, Linda
    Solda, Caterina
    Tovoli, Francesco
    Vivaldi, Caterina
    Lonardi, Sara
    Silletta, Marianna
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Himmelsbach, Vera
    Montes, Margarida
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    LIVER INTERNATIONAL, 2024, 44 (05) : 1108 - 1125
  • [46] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Chen, Ching-Tso
    Feng, Yin-Hsun
    Yen, Chia-Jui
    Chen, San-Chi
    Lin, Yun-Tzu
    Lu, Li-Chun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Shao, Yu-Yun
    HEPATOLOGY INTERNATIONAL, 2022, 16 (05) : 1199 - 1207
  • [47] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Ching-Tso Chen
    Yin-Hsun Feng
    Chia-Jui Yen
    San-Chi Chen
    Yun-Tzu Lin
    Li-Chun Lu
    Chih-Hung Hsu
    Ann-Lii Cheng
    Yu-Yun Shao
    Hepatology International, 2022, 16 : 1199 - 1207
  • [48] Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
    Kudo, Masatoshi
    LIVER CANCER, 2021, 10 (02) : 85 - 93
  • [49] Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
    Yoo, Changhoon
    Kim, Jwa Hoon
    Ryu, Min-Hee
    Park, Sook Ryun
    Lee, Danbi
    Kim, Kang Mo
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Lee, Joycelyn
    Tai, David
    Chan, Stephen Lam
    Ryoo, Baek-Yeol
    LIVER CANCER, 2021, 10 (02) : 107 - 114
  • [50] A Case of First-line Atezolizumab Plus Bevacizumab Use in Recurrence of Combined Hepatocellular Cholangiocarcinoma After Surgical Resection
    Moffat, Gordon T.
    Duan, Kai
    Knog, Jennifer J.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 14 (05)
12345